111 related articles for article (PubMed ID: 9858900)
1. Doxorubicin cardiotoxicity and serum lipid increase is prevented by dextrazoxane (ICRF-187).
Samelis GF; Stathopoulos GP; Kotsarelis D; Dontas I; Frangia C; Karayannacos PE
Anticancer Res; 1998; 18(5A):3305-9. PubMed ID: 9858900
[TBL] [Abstract][Full Text] [Related]
2. The effect of doxorubicin and its analogue mitoxantrone on cardiac muscle and on serum lipids: an experimental study.
Koutinos G; Stathopoulos GP; Dontas I; Perrea-Kotsarelis D; Couris E; Karayannacos PE; Deliconstantinos G
Anticancer Res; 2002; 22(2A):815-20. PubMed ID: 12014656
[TBL] [Abstract][Full Text] [Related]
3. Investigation of doxorubicin tissue toxicity: does amifostine provide chemoprotection? An experimental study.
Rigatos SK; Stathopoulos GP; Dontas I; Perrea-Kotsarelis D; Couris E; Karayannacos PE; Deliconstantinos G
Anticancer Res; 2002; 22(1A):129-34. PubMed ID: 12017274
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
[TBL] [Abstract][Full Text] [Related]
5. Cardiotoxicity of doxorubicin/paclitaxel combination in rats: effect of sequence and timing of administration.
Saad SY; Najjar TA; Alashari M
J Biochem Mol Toxicol; 2004; 18(2):78-86. PubMed ID: 15122649
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of adriamycin cardiotoxicity by 5-fluorouracil: a potential free oxygen radical scavenger.
Stathopoulos GP; Malamos NA; Dontas I; Deliconstantinos G; Perrea-Kotsareli D; Karayannacos PE
Anticancer Res; 1998; 18(6A):4387-92. PubMed ID: 9891497
[TBL] [Abstract][Full Text] [Related]
7. Role of (+-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) in modulating free radical scavenging enzymes in doxorubicin-induced cardiomyopathy.
Alderton P; Gross J; Green MD
Cancer Res; 1990 Aug; 50(16):5136-42. PubMed ID: 2116226
[TBL] [Abstract][Full Text] [Related]
8. An increase of serum lipids after cumulative doses of doxorubicin and epirubicin in experimental animals.
Stathopoulos GP; Papadopoulos NG; Stephanopoulou A; Dontas I; Kotsarelis D; Karayannacos PE
Anticancer Res; 1996; 16(6B):3429-33. PubMed ID: 9042202
[TBL] [Abstract][Full Text] [Related]
9. Dexrazoxane pre-treatment protects skinned rat cardiac trabeculae against delayed doxorubicin-induced impairment of crossbridge kinetics.
de Beer EL; Bottone AE; van Rijk MC; van der Velden J; Voest EE
Br J Pharmacol; 2002 Apr; 135(7):1707-14. PubMed ID: 11934811
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines.
Herman EH; Zhang J; Hasinoff BB; Chadwick DP; Clark JR; Ferrans VJ
Cancer Chemother Pharmacol; 1997; 40(5):400-8. PubMed ID: 9272116
[TBL] [Abstract][Full Text] [Related]
11. Ameliorative effects of ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] on the cardiotoxicity induced by doxorubicin or by isoproterenol in the mouse.
Flandina C; Sanguedolce R; Rausa L; D'Alessandro N
Res Commun Chem Pathol Pharmacol; 1990 Dec; 70(3):259-72. PubMed ID: 2128759
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effectiveness of (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles.
Herman EH; Ferrans VJ; Myers CE; Van Vleet JF
Cancer Res; 1985 Jan; 45(1):276-81. PubMed ID: 3917371
[TBL] [Abstract][Full Text] [Related]
13. Esorubicin cardiotoxicity in vitro: antagonism by pimobendan.
Galatulas I; Bossa R; Efstathiu G; Ninci MA
Acta Physiol Hung; 1990; 75 Suppl():123-4. PubMed ID: 2371838
[No Abstract] [Full Text] [Related]
14. Doxorubicin-induced apoptosis in spontaneously hypertensive rats: differential effects in heart, kidney and intestine, and inhibition by ICRF-187.
Zhang J; Clark JR; Herman EH; Ferrans VJ
J Mol Cell Cardiol; 1996 Sep; 28(9):1931-43. PubMed ID: 8899552
[TBL] [Abstract][Full Text] [Related]
15. Protective effect of aminoguanidine against cardiovascular toxicity of chronic doxorubicin treatment in rats.
Mostafa AM; Nagi MN; Al Rikabi AC; Al-Shabanah OA; El-Kashef HA
Res Commun Mol Pathol Pharmacol; 1999; 106(3):193-202. PubMed ID: 11485049
[TBL] [Abstract][Full Text] [Related]
16. Effects of pyrroline and pyrrolidine nitroxides on lipid peroxidation in heart tissue of rats treated with doxorubicin.
Koceva-Chyła A; Gwoździński K; Kochman A; Stolarska A; Jóźwiak Z
Cell Mol Biol Lett; 2003; 8(1):179-83. PubMed ID: 12655372
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model.
Alderton PM; Gross J; Green MD
Cancer Res; 1992 Jan; 52(1):194-201. PubMed ID: 1727379
[TBL] [Abstract][Full Text] [Related]
18. Electrocardiographic and biochemical evidence for the cardioprotective effect of vitamin E in doxorubicin-induced acute cardiotoxicity in rats.
Puri A; Maulik SK; Ray R; Bhatnagar V
Eur J Pediatr Surg; 2005 Dec; 15(6):387-91. PubMed ID: 16418954
[TBL] [Abstract][Full Text] [Related]
19. Nitric oxide and oxidative stress in brain and heart of normal rats treated with doxorubicin: role of aminoguanidine.
Abd El-Gawad HM; El-Sawalhi MM
J Biochem Mol Toxicol; 2004; 18(2):69-77. PubMed ID: 15122648
[TBL] [Abstract][Full Text] [Related]
20. Effects of dexrazoxane and amifostine on evolution of Doxorubicin cardiomyopathy in vivo.
Bjelogrlic SK; Radic J; Radulovic S; Jokanovic M; Jovic V
Exp Biol Med (Maywood); 2007 Dec; 232(11):1414-24. PubMed ID: 18040065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
